Dermatology

A summary of new data on tralokinumab in atopic dermatitis, presented at conferences/symposia held between September and October 2024.

AD is one of the most common inflammatory skin conditions,1-4 with global prevalence estimated to be 2.6% (adults: approximately 2.0%;…

Zink opened the session by recapping key efficacy data for ruxolitinib cream in non-segmental vitiligo from the TRuE-V1/2 registration…

This article has now been retracted and a retraction statement has been published.

Nemolizumab is an anti-IL-31Rα monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and…

​​Epigenetic changes drive skin aging by silencing the expression of youthful genes. Experts discussed the discovery of epicelline, an…

​​A review highlighting the need to improve vitiligo care through understanding the role of the JAK-STAT pathway, early diagnosis and…

​Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based on…